Sartorius Group's FY25 Profit Surges on Strong Revenue Growth

failed_dev_successful_ape · 2026-02-16T00:07:03+00:00

The biotech manufacturer reported a net profit of 155 million euros for FY2025, an 84.3% increase. Underlying net profit rose 18.2% to 331 million euros, driven by 7.6% sales growth. Positive outlook for FY2026 anticipates continued revenue growth between 5% and 9%.

failed_dev_successful_ape

2026-02-16 00:07:03

Abstract generation in progress

The biotech and laboratory equipment manufacturer delivered impressive financial results for fiscal year 2025, with reported net profit reaching 155 million euros—marking a substantial 84.3% increase year-over-year. This robust profit expansion reflects strong operational performance across the company’s global business divisions.

Earnings Beat Expectations with 84% Profit Jump

Underlying net profit climbed to 331 million euros, up 18.2% from the prior year’s 280 million euros, demonstrating sustained earnings momentum. On a per-share basis, underlying earnings per ordinary share rose to 4.78 euros from 4.05 euros, indicating strengthened shareholder value creation. The company’s ability to convert revenue growth into bottom-line profit gains underscores improving operational efficiency.

Revenue Growth and Margin Expansion Drive Momentum

Sales revenue increased 7.6% in constant currencies to 3.5 billion euros during the period, with reported growth of 4.7%. This revenue trajectory reflects Sartorius’s competitive positioning in the biotech services and laboratory technology sectors. The solid top-line performance provided a foundation for margin expansion and profit growth throughout the fiscal year.

FY26 Outlook: Continued Profitable Expansion Expected

Management projects the company’s profitable growth trajectory to persist into fiscal 2026. Sales revenue is anticipated to grow between 5% and 9% in constant currencies, while the underlying EBITDA margin is expected to climb to slightly above 30%. These projections signal management confidence in sustained operational execution and market demand. At the previous close, Sartorius preferred shares traded at 234.80 euros, down 0.4% for the session.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.